Home Immunicom Inc.

Immunicom Inc.

Immunicom Secures $11 Million in Series B Investment Round

Several private equity family offices participated in the Series B financing which now increases Immunicom's overall capital raised to $20 million.

Must Read

New Study Validates Rigorous Safety Measures Needed To Reduce Mercury Exposure During Dental Amalgam Filling Removal

"For decades, our non-profit organization has been concerned about this issue and collected research about amalgam fillings, all of which contain approximately 50% mercury, a known neurotoxin," explains IAOMT President Michael Rehme, DDS, NMD.  "Based on this science, we have strongly recommended that safety measures be enacted for dental procedures involving these silver-colored fillings, and we have also intensely advocated for the end of dental amalgam usage."